New oral anticoagulants in elderly adults: Evidence from a meta-analysis of randomized trials

Journal of the American Geriatrics Society

Volumn 62, Issue 5, 2014, Pages 857-864

  Sardar, Partha ^a   Chatterjee, Saurav ^b   Chaudhari, Shobhana ^a   Lip, Gregory Y H ^c  

^a METROPOLITAN HOSPITAL CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

elderly; meta analysis; new anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN;

AGED; AGING; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHECKLIST; CINAHL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MEDLINE; OUTCOME ASSESSMENT; PRISMA CHECKLIST; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ELDERLY; META-ANALYSIS; NEW ANTICOAGULANTS;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; INCIDENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; THROMBOEMBOLISM; WORLD HEALTH;

EID: 84900522812     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12799     Document Type: Article

References (37)

1. Robert-Ebadi H, Le Gal G, Righini M,. Use of anticoagulants in elderly patients: Practical recommendations. Clin Interv Aging 2009; 4: 165-177.
2. Spyropoulos AC, Merli G,. Management of venous thromboembolism in the elderly. Drugs Aging 2006; 23: 651-671.
3. Deedwania PC,. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med 2013; 126: 289-296.
4. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
5. Lip GY, Halperin JL,. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010; 123: 484-488.
6. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
7. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272.
8. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-294.
9. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR,. Venous thrombosis in the elderly: Incidence, risk factors and risk groups. J Thromb Haemost 2010; 8: 2105-2112.
10. Zarraga IG, Kron J,. Oral anticoagulation in elderly adults with atrial fibrillation: Integrating new options with old concepts. J Am Geriatr Soc 2013; 61: 143-150.
11. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-e88S.
12. Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012; 345: e7498.
13. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-2391.
14. Jacobs JM, Stessman J,. New anticoagulant drugs among elderly patients is caution necessary? Comment on "The use of dabigatran in elderly patients". Arch Intern Med 2011; 171: 1287-1288.
15. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1286.
16. Harper P, Young L, Merriman E,. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866.
17. Wychowski MK, Kouides PA,. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46: e10.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
19. Higgins JPT, Altman DG, Sterne JAC,. Assessing risk of bias in included studies. In:, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at http://www.cochrane-handbook.org Accessed April 5, 2013.
20. Schulman S, Kearon C,. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3: 692-694.
21. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
22. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
23. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
24. Cohen AT, Spiro TE, Büller HR, et al.; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513-523.
25. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
26. Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
27. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
28. Connolly SJ, Eikelboom J, Joyner C, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
29. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
31. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
32. Halperin J, Wojdyla D, Piccini JP, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF Trial. Stroke 2012; 43: A148.
33. Halvorsen S, Wallentin L, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2013; 61 (Suppl 10): E315.
34. Potpara TS, Lip GY, Apostolakis S,. New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart 2012; 98: 1341-1347.
35. Southworth MR, Reichman ME, Unger EF,. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
36. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
37. Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study. BMJ Open 2013; 3. pii: e002758.